FDA, Tirzepatide

The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to cheaper versions could end.
FDA approves first medication for obstructive sleep apnea — which also promotes weight loss
The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).
FDA confirms shortage of weight loss drug tirzepatide is over, gives compounders a grace period
The FDA on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will put a stop to companies making cheaper copies.
Weight Loss Drug Tirzepatide Now Approved for Sleep Apnea in Adults With Obesity
The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.
Obesity Drug Zepbound Approved for Obstructive Sleep Apnea
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to severe OSA in people with obesity.
US FDA approves use of weight loss drug for sleep apnoea: Here’s all you need to know
The drug has been approved for use in combination with a low-calorie diet and increased physical activity in those with moderate to severe OSA. This shows that the weight-loss drug has multifarious uses other than controlling type-2 diabetes and obesity.
The Zepbound Shortage Is Over — Here's What to Expect if You've Been Using an Off-Brand Version
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
‘An insatiable itch’: Why some people are turning to weight-loss medications to help quiet food noise
Savannah Mendoza used to spend most of her paychecks on food delivery apps and at fast food drive-thrus, trying to satisfy a ...
Elon Musk Shares Christmas Weight-Loss Post: 'Ozempic Santa'
Elon Musk has admitted to taking a weight-loss drug in a Christmas Day post on X, formerly Twitter, as he shared a picture of ...
MedPage Today7d
FDA Says Compounded Tirzepatide Must Exit the Market
Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...
KSAT3h
Doc Talk: University Health doctor answers viewers’ questions
University Health medical director Dr. Leo Lopez joined KSAT anchor Stephania Jimenez and KSAT reporter Daniela Ibarra to ...
24/7 Wall St20h
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and ...
India Infoline1d
Biocon Gets USFDA Clearance and EU Nod for Diabetes Drug
Liraglutide, Semaglutide and Tirzepatide generics were some of the major structural growth drivers in financial year 2026.
Off-brand versions of Lilly weight loss drug must be pulled off market, could mean higher prices
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...